publication date: Jul. 14, 2017

In Brief Steven Piantadosi steps down at Cedars-Sinai to focus on clinical trial design

Steven Piantadosi has stepped down from his position as director of Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute.

The text of an announcement distributed to the faculty and staff on July 11 follows:

“After 10 years building the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute from its early outset, and significantly enhancing our capabilities in cancer research and clinical care, Dr. Piantadosi has identified this as an ideal time to relinquish leadership and devote his time and attention to his longstanding academic and clinical focus of clinical trial design. To enable Cedars-Sinai to continue to benefit from Dr. Piantadosi’s expertise on an institution-wide basis, we have asked him to lead a newly established Cedars-Sinai Clinical Trials Design Research Center. Building on Dr. Piantadosi’s nationally recognized talents, this new program will be devoted to academic research opportunities for trial design and statistical planning. He will be moving into this new role on August 1.

“We are initiating a national search for Dr. Piantadosi’s successor, with the search committee to be chaired by Dr. Bruce Gewertz. Dr. Howard Sandler has agreed to serve as interim director of the Samuel Oschin Comprehensive Cancer Institute.

“We are truly appreciative of Dr. Piantadosi’s leadership over the past 10 years. He has built a durable cancer research … Continue reading Steven Piantadosi steps down at Cedars-Sinai to focus on clinical trial design

To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2017 The Cancer Letter Inc.